• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [18637 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2001     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Alternatives to blood transfusion]
2015     Norwegian Institute of Public Health (NIPH) [Alternatives of plasma for transfusion to patients]
2015     Haute Autorite de sante (HAS) [Alternative(s) to 99mTc-sestamibi preoperative scintigraphy for the localization of hypersecreting parathyroid glands in the event of complete shortage of 99mTechnetium (99mTc)]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Alternative methods for the treatment of post-menopausal troubles]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Alprostadil for nonrevascularizable critical lower limb ischemia]
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Alpha1 antitrypsin]
2012     Andalusian Health Technology Assessment Area (AETSA) [Allomap genetic test for cardiac transplant rejection]
2009     Committee for New Health Technology Assessment (CNHTA) [Allo skin graft]
1999     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Allergic diseases: suggestions concerning organization of prevention, diagnostics and treatment (funded by DIHTA)]
2012     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aliskiren/amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Alirocumab for patients with hypercholesterolemia]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alirocumab - benefit assessment according to §35a Social Code Book V]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alirocumab - addendum to commission A15-47]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alipogene tiparvovec - assessment according to §35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Alglucosidase alpha (Myozyme) for treatment of patients with late-onset Pompe disease]
2014     Andalusian Health Technology Assessment Area (AETSA) [Alglucosidase alfa (Myozyme ®) in late-onset Pompe disease]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Alemtuzumab in multiple sclerosis]
2016     Institute for Clinical Effectiveness and Health Policy (IECS) [Alemtuzumab for multiple sclerosis]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Alefacept (Amevive(R)) for the treatment of severe psoriasis]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC) - benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (non-small-cell lung cancer) - addendum to commission A17-19]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Albutrepenonacog alfa - assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Albumin Dialysis and Molecular Adsorbent Recirculating System (MARS) in the treatment of liver failure]
2011     Haute Autorite de sante (HAS) [Albumin (or protein) to creatinine ratios in the diagnosis of chronic kidney disease in adults]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Albiglutide - benefit assessment according to section 35a Social Code Book V (dossier assessment)]
2008     Committee for New Health Technology Assessment (CNHTA) [AGL gene, mutation[sequencing]]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Age-related macular degeneration: the role of current treatment strategies]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Aflibercept for age-related macular degeneration and central retinal vein occlusion]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Zaltrap) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (new therapeutic indication) – benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (new therapeutic indication) - benefit assessment according to §35a Social Code Book V]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Eylea) extension of approval: benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (extension of approval) - benefit assessment according to section 35a Social Code Book V (dossier assessment)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Addendum to Commission A14-32)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib: benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib: benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib (new therapeutic indication) - benefit assessment according to §35a Social Code Book V]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afamelanotide - assessment according to §35a (para. 1, sentence 10) Social Code Book V]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Advisability of expanding the Québec newborn blood screening program]
2016     National Evidence-based Healthcare Collaborating Agency (NECA) [Advantages of vestibular rehabilitation on the vestibular neuritis]
2008     Committee for New Health Technology Assessment (CNHTA) [Adenovirus, nested PCR]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Addendum to the notice on the efficacy of rehabilitative interventions and pharmacological therapies for children aged 2 to 12 Years with autism spectrum disorder (ASD)]
2011     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to the final report A09-02 (benefit assessment of prasugrel)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-26 (empagliflozin)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-21 (fingolimod)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-19 (mirabegron)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-18 (simeprevir)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A14-14 (dimethyl fumarate)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-12 (canagliflozin)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A14-05 (sofosbuvir)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-44 (ipilimumab)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-37 (regorafenib)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-35 (dabrafenib)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-33 (enzalutamide)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A13-17 (vildagliptin/metformin)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-16 (vildagliptin)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A13-10 (pertuzumab)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-09 (vandetanib)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-06 (abiraterone acetate [new therapeutic indication])]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-05 (fidaxomicin)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A13-03 (sitagliptin/metformin)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A12-16 Saxagliptin/metformin]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A12-15 Crizotinib]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Adaptation to the Catalan health care system of the clinical practice guideline 'Management of major depression in adults']
2013     Basque Office for Health Technology Assessment (OSTEBA) [Adaptation and assessment of an online research methodology training course for nurses]
2009     Committee for New Health Technology Assessment (CNHTA) [ADAMTS 13 Activity]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis]
2006     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Adalimumab for treating rheumatoid arthritis]
2013     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Acute pain treatment on postoperative and medical non-surgical wards]
2016     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Acute neck and back pain: preventive interventions – effects of physical training, manual treatment and cognitive behavioral interventions]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for treating lumbago]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for lateral epicondylitis]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for headache]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for carpal tunnel syndrome]
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Acupuncture - areas of application, current evidence and proven indications]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Actualization: radiofrequency sympathetic denervation of the renal arteries for refractory arterial hypertension]
2011     The Regional Health Technology Assessment Centre (HTA-centrum) [Active mobilization after flexor tendon repairs in zone II of the hand]
2011     The Regional Health Technology Assessment Centre (HTA-centrum) [Active mobilization after flexor tendon repairs in zone II of the hand]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Active knee motion devices in the treatment of anterior cruciate ligament ruptures]
2013     Andalusian Health Technology Assessment Area (AETSA) [Active immunotherapy for breast cancer]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aclidinium/formoterol: benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aclidinium bromide - benefit assessment according to §35a Social Code Book V]
2012     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aclidinium bromide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2009     Committee for New Health Technology Assessment (CNHTA) [Acellular dermal graft]
2008     Committee for New Health Technology Assessment (CNHTA) [Access flow measurement for hemodialysis]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate (New therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2011     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Abemaciclib, palbociclib and ribociclib in breast cancer]
2007     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Abatacept in the treatment of rheumatoid arthritis; systematic review and economic evaluation]
2009     Committee for New Health Technology Assessment (CNHTA) [AB0-Rh(D) blood grouping automation test using CAT (column agglutination technology)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [A16-05 dabrafenib/trametinib - addendum to commissions A15-39 and A15-40]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A systematic review of the diagnostic accuracy of FDG PET/PET-CT for fever of unknown origin]
2021     Center for Drug Evaluation (CDE) [A systematic review of the comparative efficacy and cost-effectiveness of current listed statins in Taiwan]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the system and execution model for health technology reassessment]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the factors influencing adherence to antidepressant therapies and the cost-effectiveness of antidepressant therapies in Korea]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the evaluation standards of osteoporosis in Korea]
2016     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the effectiveness and needs of patient education in patients with rheumatoid arthritis]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on Korean adolescents' risk factors of suicide]
2010     Andalusian Health Technology Assessment Area (AETSA) [A study on efficacy, effectivity and efficiency of Intensity Modulated Radiotherapy (IMRT). Utility for treatment of breast and central nervous system neoplasms and sarcomas of bones and soft tissue]